Recursion Pharmaceuticals Stock Market Value
| RXRX Stock | USD 6.53 0.13 2.03% |
| Symbol | Recursion |
Recursion Pharmaceuticals Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Recursion Pharmaceuticals. If investors know Recursion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Recursion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.57) | Revenue Per Share | Quarterly Revenue Growth 1.476 | Return On Assets | Return On Equity |
The market value of Recursion Pharmaceuticals is measured differently than its book value, which is the value of Recursion that is recorded on the company's balance sheet. Investors also form their own opinion of Recursion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Recursion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Recursion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Recursion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Recursion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Recursion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Recursion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Recursion Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Recursion Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Recursion Pharmaceuticals.
| 12/19/2024 |
| 01/18/2025 |
If you would invest 0.00 in Recursion Pharmaceuticals on December 19, 2024 and sell it all today you would earn a total of 0.00 from holding Recursion Pharmaceuticals or generate 0.0% return on investment in Recursion Pharmaceuticals over 30 days. Recursion Pharmaceuticals is related to or competes with Absci Corp, Affimed NV, Sana Biotechnology, Relay Therapeutics, Immix Biopharma, Hepion Pharmaceuticals, and Enveric Biosciences. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by i... More
Recursion Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Recursion Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Recursion Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.21 | |||
| Information Ratio | 0.0173 | |||
| Maximum Drawdown | 34.19 | |||
| Value At Risk | (8.39) | |||
| Potential Upside | 10.42 |
Recursion Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Recursion Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Recursion Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Recursion Pharmaceuticals historical prices to predict the future Recursion Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0271 | |||
| Jensen Alpha | 0.1116 | |||
| Total Risk Alpha | (0.02) | |||
| Sortino Ratio | 0.0202 | |||
| Treynor Ratio | 0.1841 |
Recursion Pharmaceuticals Backtested Returns
At this stage we consider Recursion Stock to be unstable. Recursion Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of 0.0203, which implies the firm had a 0.0203% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Recursion Pharmaceuticals, which you can use to evaluate the volatility of the company. Please check Recursion Pharmaceuticals' Semi Deviation of 5.13, coefficient of variation of 4518.66, and Risk Adjusted Performance of 0.0271 to confirm if the risk estimate we provide is consistent with the expected return of 0.13%. Recursion Pharmaceuticals has a performance score of 1 on a scale of 0 to 100. The company holds a Beta of 0.68, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Recursion Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Recursion Pharmaceuticals is expected to be smaller as well. Recursion Pharmaceuticals right now holds a risk of 6.15%. Please check Recursion Pharmaceuticals maximum drawdown, skewness, and the relationship between the total risk alpha and downside variance , to decide if Recursion Pharmaceuticals will be following its historical price patterns.
Auto-correlation | -0.61 |
Very good reverse predictability
Recursion Pharmaceuticals has very good reverse predictability. Overlapping area represents the amount of predictability between Recursion Pharmaceuticals time series from 19th of December 2024 to 3rd of January 2025 and 3rd of January 2025 to 18th of January 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Recursion Pharmaceuticals price movement. The serial correlation of -0.61 indicates that roughly 61.0% of current Recursion Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.61 | |
| Spearman Rank Test | -0.28 | |
| Residual Average | 0.0 | |
| Price Variance | 0.33 |
Recursion Pharmaceuticals lagged returns against current returns
Autocorrelation, which is Recursion Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Recursion Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of Recursion Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that Recursion Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Recursion Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Recursion Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Recursion Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Recursion Pharmaceuticals stock over time.
Current vs Lagged Prices |
| Timeline |
Recursion Pharmaceuticals Lagged Returns
When evaluating Recursion Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Recursion Pharmaceuticals stock have on its future price. Recursion Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Recursion Pharmaceuticals autocorrelation shows the relationship between Recursion Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in Recursion Pharmaceuticals.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.